ZURICH (Reuters) - Novartis
"We are planning to respond but we haven't submitted yet," a spokesman said on Monday.
U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.
Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.
(Reporting by John Miller)